

REVIEW

Microglia heterogeneity in health and disease

 Shilauni Dadwal¹  and Michael T. Heneka^{1,2} 
¹ Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belval, Luxembourg

² Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA, USA

Keywords

distribution; microglial origin; neurodegenerative diseases; regulation; subtypes

Correspondence

 M. T. Heneka, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 6 Avenue du Swing, 4367 Belval, Luxembourg
 Tel: +352 621 712 820
 E-mail: michael.heneka@uni.lu

(Received 11 August 2023, revised 12 October 2023, accepted 8 November 2023)

doi:10.1002/2211-5463.13735

Edited by Koji Yamanaka

Microglia, the resident immune cells of the central nervous system (CNS), have received significant attention due to their critical roles in maintaining brain homeostasis and mediating cerebral immune responses. Understanding the origin of microglia has been a subject of great interest, and emerging evidence suggests that microglia consist of multiple subpopulations with unique molecular and functional characteristics. These subpopulations of microglia may exhibit specialized roles in response to different environmental cues as in disease conditions. The newfound understanding of microglial heterogeneity has significant implications for elucidating their roles in both physiological and pathological conditions. In the context of disease, microglia have been studied rigorously as they play a very important role in neuroinflammation. Dysregulated microglial activation and function contribute to chronic inflammation. Further exploration of microglial heterogeneity and their interactions with other cell types in the CNS will undoubtedly pave the way to novel therapeutic strategies targeting microglia-mediated pathologies. In this review, we discuss the latest advances in the field of microglia research, focusing specifically on the origin and subpopulations of microglia, the populations of microglia types in the brains of patients with neurodegenerative diseases, and how microglia are regulated in the healthy CNS.

The central nervous system (CNS), the most intricate human organ system, comprises billions of neurons coordinating the intricate interplay of thoughts, emotions, and physiological functions. However, the complex network requires constant surveillance and protection to maintain its delicate balance. So, in the brain, microglia serve as the guardians, playing a vital role in immune defense and maintaining cerebral

homeostasis. As part of the innate immune system, microglia continuously monitor the CNS for potential internal and external threats [1–3]. In addition to their crucial role in defending the CNS against pathogens, microglia also contribute significantly to controlling neuronal proliferation, synapse formation, and elimination as well as debris clearance [4–6]. Moreover, they actively participate in remodeling neuronal circuits in

Abbreviations

AD, Alzheimer's disease; ALS, amyotrophic lateral sclerosis; APOE, apolipoprotein; APP, amyloid precursor protein; ASD, autism spectrum disorder; A β -plaques, amyloid beta plaques; BDNF, brain-derived neurotrophic factor; CCL4, C-C Motif chemokine ligand 4; CCR9, CC Chemokine receptor type 9; CD40, cluster of Differentiation 4; CNS, central nervous system; CSF1, colony stimulating factor 1; CX3CR1, CX3C receptor 1; CyTOF, cytometry by time of flight; DAMs, disease-associated microglia; EAE, experimental autoimmune encephalomyelitis; EGA, estimated gestational age; EGFP, enhanced green fluorescent protein; ETS, E-twenty six; GABA, gamma-aminobutyric acid; H3K27me3, H3 lysine 27 trimethylation; IBA1, ionized calcium-binding adaptor molecule 1; IL10, interleukin 10; IL4, interleukin 4; Irf8, interferon regulatory factor 8; KSPG, Keratan sulfate proteoglycan microglia; MGnD, neurodegenerative microglia; MS, multiple sclerosis; NGF, Nerve Growth Factor; P2RY12, purinergic receptor P2Y, G-protein coupled 12; PD, Parkinson's disease; PGE2, prostaglandin E2; PRC2, polycomb repressive complex 2; PRR, pattern recognition receptor; RMS, rostral migratory stream; SVZ, subventricular zone; TNF- α , tumor necrosis factor-alpha; TREM2, triggering receptor expressed on myeloid cells 2.

postnatal mice [7]. Given the diverse functions, it is not surprising, given their diverse functions, that microglia represent a heterogeneous myeloid cell population, which is indispensable for the CNS in health and disease [8].

Considering the significance of microglia, it is important to explore their origin, their various subpopulations, and their precise mode of action. Microglia, as essential neuroglial cells, account for 5–20% of the entire glial population in mice while in humans, they constitute 0.5–16.6% of the total population [9].

In this article, we review the recent findings in the field of microglia research with a focus on their heterogeneity. The identification of distinct microglial subtypes and their unique functional characteristics have revolutionized our understanding of their roles in brain development, homeostasis, and disease processes. Understanding the modulation of these different microglial subpopulations will be key to develop precise therapeutic interventions targeting CNS innate immune mechanisms.

Origin of microglia

Over the past 160 years, multiple hypotheses about the origin of microglia have emerged. W. Ford Robertson was the first to introduce the term “mesoglia”, a phagocytic element derived from the mesoderm, distinct from neurons and other CNS cells. In 1856, Virchow coined the term “neuroglia” (originally “Nervenkitt”), referring to these cells as “nerve-glue,” which was later translated to “neuroglia” [10]. Santiago Ramon y Cajal, a prominent scientist in the field of neuroscience, renamed the cells the “third element of the nervous system.” A student of his, Pio del Río-Hortega, continued working on these cells and made significant contributions to the understanding of the “third element of the nervous system.” Del Río-Hortega studied the third element of the nervous system using silver carbonate impregnation staining. He redefined the concept of the “third element” based on its morphology and function, which he named “microglia cells.” Microglia cells are characterized as a small population of phagocytic and migratory immune cells in the CNS, distinguishing them from neurons, astrocytes, and oligodendroglia, which are of neuroectodermal origin [11].

In murine models, the precise origin of microglia has sparked controversies. It was believed that microglia are present during early development, suggesting that they originated from embryonic progenitors. Del Río-Hortega proposed an additional possibility, that microglia could derive from meningeal macrophages. Another hypothesis during that era was that microglia could originate from blood monocytes [10,11]. Ashwell

and colleagues initially observed the presence of amoeboid microglia cells at E11.0 in the fetal mouse cerebellum and later in the rat forebrain [12,13]. Subsequently, Sorokin and his colleagues detected macrophage precursors and macrophage-like cells in the embryonic mesenchyme and blood vessels in rats starting from E10.5, highlighting the brain as the first organ to be colonized [14].

The origin of microglia was studied using genetic mapping, which revealed that microglia originate from yolk sac primitive macrophages [15–19]. During embryonic development in mice, between embryonic days E8.0 and E10.0, there is blood vessel formation and remodeling [20]. Around E7.0, precursor cells expressing vascular endothelial growth factor migrate from the primitive streak to the proximal yolk sac, where they form blood islands. These blood islands house the multilineage c-kit⁺ erythromyeloid yolk sac precursor cells that give rise to microglia [21,22]. The yolk sac precursor cells mature from A1 (CD45⁺ c-kit^{lo} CX3CR1[−] F4/80[−]) to A2 (CD45⁺ c-kit[−] CX3CR1⁺ F4/80^{hi}) amoeboid macrophages in the blood islands and cephalic mesenchyme. Eventually, they acquire the phenotype of mature macrophages in the neuroepithelium by E10.5 [23]. Fate mapping studies using genetic targeting of hematopoietic precursors expressing the runt-related transcription factor Runx1 between E6.5 and E10.5 have shown that yolk sac macrophages are specified between E7.0 and E7.5 [15]. An interesting study demonstrated that normal yolk sac hematopoiesis from E9.5 to 10.5 in Ncx-1 knockout mice causes the absence of brain microglia progenitors. This supports the notion that brain recruitment of yolk sac progenitors depends on a functional circulatory system [15]. Microglia enter the developing brain through the leptomeninges and lateral ventricles at E9.5 and then distribute within the cortical walls from both directions. The speed of migration, proliferation rates, and maturation of microglia vary based on the region and developmental stage [15,24,25]. In early postnatal weeks of mouse development, there is an increase in the number of microglia cells. Subsequently, there is a gradual decrease in their number, reaching approximately 50% of the peak density. From Week 5 to 6, microglia density stabilizes [26].

In human fetuses, microglia-like cells can be detected as early as 3 weeks of the estimated gestational age (EGA) [27]. By Week 4.5, amoeboid microglial cells migrate into the cerebral wall via the pial surface, ventricle, and choroid plexus [28,29]. In the white matter, subplate, and cortical plate layers, radial and tangential migration was observed and then at 12–13 gestational weeks, the second wave of microglia was observed via the vasculature [29,30]. Around

Week 9, colonization of the spinal cord begins, and by Week 16, there is a significant influx and distribution of microglia throughout the entire CNS. It takes approximately 22 weeks for microglia to adopt a ramified form and to develop widely distributed processes. Importantly, well-differentiated microglia are detected at 35 weeks of pregnancy [28,30–33]. These studies provide strong evidence that microglia originate from embryonic hematopoietic precursors that populate the CNS before birth and prior to bone marrow hematopoiesis. In zebrafish, yolk sac macrophages initially invade the entire cephalic mesenchyme and subsequently infiltrate epithelial tissues, including the brain. Additionally, other macrophages enter the blood circulation, indicating that colonization occurs independently of the blood circulation [34,35]. Summarizing the current knowledge suggests the origin of microglia is from yolk sac primitive macrophages, and the colonization takes place before the formation of neuroectoderm-derived cell types, such as astrocytes and oligodendrocytes. Microglia remain in the brain throughout life and self-renew [15–19,22,25,30,36].

Microglia subpopulations

In the CNS, microglia are non-uniformly distributed, as observed by Lawson and colleagues using polyclonal antiserum targeting the F4/80 marker. Their study revealed that the telencephalon region has the highest density of microglia, followed by the diencephalon, mesencephalon, and rhombencephalon, which contain fewer microglia. Furthermore, the gray matter is more densely populated with microglia compared with the white matter [37]. These studies have proposed the existence of different microglial subtypes, each associated with a distinct molecular signature [38]. Understanding these potential subtypes will provide insights into the differential responses of microglia to intrinsic and extrinsic stimuli i.e.; microglia near A β -plaques show a neurodegenerative profile controlled by TREM2-APOE, and targeting APOE can revert them to a healthy state, reducing apoptotic neuron phagocytosis [39–44].

What makes a cell subtype? Traditionally, a cell type is defined based on its host tissue, morphology, lineage, function, and molecular composition [45]. From a historical perspective, del Río-Hortega already defined a microglial subtype known as “satellite microglia,” which are located in close proximity to neuronal cell bodies [46]. This early observation highlights the concept of microglial subtypes based on their distinct anatomical localization and association with specific cellular components or morphological structures. It is

important to continue investigating and characterizing microglial subtypes to gain a deeper understanding of their functional diversity and associated molecular signatures. Microglia distribution in the CNS is not only variable concerning localization but also varies in morphology based on their association with different cellular components such as neuronal cell bodies, dendrites, axons, myelinated axons, and blood vessels. This variability is also reflected at the transcriptional level [47,48]. Several studies have mounted evidence that microglia isolated from unchallenged adult murine brain exhibit variability in gene expression patterns depending on the brain regions which they were isolated from. Various markers such as CD40, CD11b, CD45, CD80, CD86, F4/80, Triggering Receptor Expressed on Myeloid Cells 2b (TREM2b), CX3CR1, and CCR9 show variable expression levels in microglia based on brain area and transcriptome analysis using preselected panels [49,50]. Furthermore, recent research by Jordão and colleagues revealed the diversity of CNS-associated macrophages in three subsets expressing high levels of Mrc1, Ms4at, Pf4, Stab1, Cbr2, CD163, and Fcrls. These subsets are associated with different CNS compartments, including the leptomeninges, choroid plexus, and perivascular space [51]. The microglia in the vicinity of these different types of neurons, as well as other glial cells such as astrocytes, oligodendrocytes, and progenitor cells, show distinct gene expression profiles under steady-state conditions. Several subtypes of microglia have been identified based on their unique genomic, morphological, and function specialization.

These subtypes include satellite microglia, keratan sulfate proteoglycan-microglia (KSPG)-microglia, microglia supporting neurogenesis, Hox8b⁺ microglia, CD11c⁺ microglia, dark microglia, and TREM2-positive-microglia (Table 1). Satellite microglia interact with the axon initial segment in the healthy brain and lose the interaction upon injury. The markers required to identify satellite microglia are IBA1, CD11b, and CX3CR1; these microglia are frequently detected in the cortex and hippocampus [52–54]. KSPG-microglia appear upon different insults, for example around motoneurons in Amyotrophic Lateral Sclerosis (ALS), and can be identified by the microglia marker IBA1, CR3, and CD11b. KSPG-microglia are mainly present in the olfactory bulb, hippocampus, and brainstem [55–57]. Microglia-supporting neurogenesis are essential for neuroblast survival and migration in the subventricular zone (SVZ)/rostral migratory stream (RMS), and their characteristics include the expression of IBA1⁺, isolectin B₄⁺, CD68⁺, P2RY12^{low}, pSTAT6⁺ cells as well as their ability to produce IL4 and IL10. Morphologically, these microglia are less ramified than microglia in

Table 1. Microglia subpopulation in the CNS.

| Microglial subpopulation | Markers | Specific brain region |
|---|---|--|
| Satellite microglia [46] | IBA1, CD11b, and CX3CR1 | Cortex and hippocampus |
| Keratan sulfate proteoglycan-microglia (KSPG)-microglia [55,56] | IBA1, CR3, and CD11b | Olfactory bulb, hippocampus, and brainstem |
| Microglia supporting neurogenesis [58] | IBA1 ⁺ , isolectin B ₄ ⁺ , CD68 ⁺ , P2RY12 ^{low} , pSTAT6 ⁺ | Olfactory, subventricular zone, and rostral migratory stream |
| Hox8b ⁺ microglia [61] | IBA1 and CD11b | Olfactory bulb and cortex of the brain |
| CD11c ⁺ microglia [64] | IBA1, CD11c, CD45 ^{low} , CX3CR1, and CCR2 ^{null} | Corpus callosum and cerebellum |
| Dark microglia [65] | IBA1 ^{low} , CX3CR1-GFP ^{low} , CD11b, TREM2, and 4D4 | The cortex, hippocampus, amygdala, and hypothalamus |
| TREM2-positive-microglia [67] | TREM2 | Cingulate cortex and lateral entorhinal cortex |

neighboring brain cells and in the olfactory, subventricular zone, and rostral migratory stream, they can be identified by the expression of CX3CR1-EGFP [58–60]. Hox8b⁺ microglia have a critical role in the functioning of the corticosteroid neuronal circuits. A deficiency of Hox8b⁺ microglia affects corticosteroid neuronal circuits negatively and leads to impaired grooming, anxiety, and altered social behaviors. Markers to identify Hox8b⁺ microglia are IBA1 and CD11b. These microglia are present in the olfactory bulb and cortex of the brain [61–63]. CD11c-positive microglia promote myelination and neurogenesis in the neonatal brain and can be identified with markers IBA1, CD11c, CD45^{low}, CX3CR1, and CCR2^{null}. CD11c⁺ microglia cells are present in the corpus callosum and cerebellum [64]. Dark microglia, which interact with blood vessels and synapses, appear dark when detected by electron microscopy and can be identified by IBA1^{low}, CX3CR1-GFP^{low}, CD11b, TREM2, and 4D4. Dark microglia can be found in the cortex, hippocampus, amygdala, and hypothalamus [65,66]. These subtypes of microglia demonstrate diversity in their localization and functional roles. The role of TREM2 microglia in Alzheimer's disease (AD) is essential for neuroprotection. However, it is important to note that not all microglia express the TREM2 receptor. TREM2-positive microglia are known for their survival and proliferation, and they tend to cluster around A β -plaques in AD [67]. In murine models, TREM2 expression in microglia varies across different brain regions. The highest levels of TREM2 expression are found in the cingulate cortex and lateral entorhinal cortex, while much lower levels are observed in regions such as the hypothalamus and habenula. Interestingly, some regions, such as the circumventricular organs, completely lack TREM2 expression [68]. These regional differences in TREM2 expression are also observed in humans. Microarray data from 101 individuals revealed significant variations

in TREM2 expression between different brain regions, particularly in the white matter and cerebellum. This suggests the presence of specific subtypes of microglia with varying roles in different brain regions, which may be relevant to the progression of AD and other neurological disorders [69]. Of note, the described pattern may vary and be dynamic over the entire lifetime and in particular during inflammatory challenges and activation.

In addition to a subpopulation of microglia defined by differential gene expressions, there are differences in the microglia population between males and females [70–73]. Microglial density in 13-week-old male mice is higher than in females, while the opposite holds true for 3-week-old mice, showcasing significant age- and gender-related variation [74]. Hormones such as estradiol also play a major role in the gender-dependent variation of microglia numbers [75,76]. During early postnatal development, male mice have more microglia in the cortex, hippocampus, and amygdala compared with females. This is linked to increased expression of CC-chemokine ligand (CCL) 20 and CCL4 due to testosterone, the primary masculinizing hormone, being aromatized to estradiol in the mouse brain. Adult female mice exhibit thicker microglia with longer processes in the hippocampus, amygdala, and cortex compared with male mice [76,77].

Microglia regulation

Microglia are crucial components of the neuroglial network in the healthy CNS. In the “homeostatic” state, microglia exhibit small cell bodies with ramified processes [78]. In this state, microglia do not overlap with the processes of neighboring cells, and each microglia cell actively surveys its immediate vicinity. While the soma of microglia remains stable, the processes constantly elongate and retract, allowing them

to constantly explore the tissue environment widely. Upon stimulation by pathogen exposure, microglia rapidly retract their processes and become mobile effector cells [2]. The activation of microglia is triggered by various immune receptors, both endogenous and exogenous, that are present on their surface and collectively described as pattern recognition receptors (PRR) [79–81]. Examples of these PRRs include Toll-like receptors (TLRs), scavenger receptors, CD36, and CD47, as well as numerous cytokine and chemokine receptors. Further surface receptors are involved in the regulation of microglial homeostasis, their interaction with neighboring cells, and immune reactivity (Table 2):

CD200 is a crucial molecule expressed on the surface of neurons, astrocytes, and oligodendrocytes. It serves as a receptor on microglia and macrophages, helping to maintain their resting state [82–84]. CX3CR1 is another essential molecule found on the surface of monocytes, macrophages, dendritic cells, and natural killer cells. Its ligand, fractalkine or neurotactin (CX3CL1), is present on neurons and interacts with microglia via CX3CR1. This interaction plays an important role in regulating microglia functions within the CNS [5,85–89]. Loss of this interaction, as seen in animal models of PD and other neurodegenerative disorders, can lead to increased neuronal cell death [85]. CD47, expressed ubiquitously on neurons, transmits “do not eat me” signals to microglia through its interaction with CD172a/Sirp alpha [84,90]. Ayata and colleagues showed that

cerebellar microglia have a unique ability for clearance, while microglia in the striatum exhibit a homeostatic surveillance phenotype [90,91]. It was also demonstrated that the suppression of clearance genes in striatal microglia is mediated by PRC2, an enzyme complex that catalyzes the repressive chromatin modification histone H3 lysine 27 trimethylation (H3K27me3). Removal of PRC2 in microglia results in enhanced clearance function in both the striatum and cerebral cortex even in the absence of dying neurons [91]. TREM2 is primarily known for its involvement in the phagocytosis of cellular debris and the downregulation of pro-inflammatory cytokines [92]. Studies showed that the deletion of TREM2 showed identical phenotypes such as enhanced inflammatory cytokine production [93,94]. Colony Stimulating Factor 1 (CSF1) plays a crucial role in regulating the survival of myeloid lineage cells in general [95]. Colony Stimulating Factor 1 binds to its receptor, CSF1R, and the absence of CSF1R results in a deficiency of several subsets of mononuclear phagocytes. Notably, in mice lacking CSF1R, microglia, are entirely absent [15,96].

Endogenous transcription factors, such as Runx1, ETS (E-twenty six) family transcription factor PU.1 shown in Fig. 1, interferon regulatory factor 8 (Irf8), and Hoxb8, play crucial roles in regulating differentiation processes during the embryonic development [15,22]. While c-myc is not directly involved in microglia development, it plays a vital role in maintaining

Table 2. Factors regulating microglia.

| Microglial regulation | Function |
|--|--|
| CD200 [82] | Helps to maintain resting state |
| CX3CR1 [85] | Regulate microglia recruitment to the site of neuroinflammation |
| CD47 [84] | Neuronal protein sends “do not eat me” signals to microglia via CD172a/Sirp alpha interaction |
| PRC2 [91] | PRC2 enzyme catalyzes H3K27me3 modification |
| TREM2 [93,94] | Role in phagocytosis of debris and reducing proinflammatory cytokines |
| CSF1 [95] | Regulate the survival of myeloid lineage |
| Runx1, ETS, PU.1, Irf8, Hoxb8 [15,22] | Regulating differentiation processes during the embryonic development |
| C-myc [97] | Essential for microglia health, regulates proliferation, and survival in the CNS |
| Ionotropic receptors [98,99] | Calcium influx and the release of pro-inflammatory molecules |
| Metabotropic receptors [98,99] | Activate intracellular signaling cascades that contribute to microglial activation and inflammation |
| Nerve Growth Factor [100] | Regulate microglial activation and survival |
| Prostaglandins E2 [101] | Modulate microglial activation and pro-inflammatory responses |
| Gamma-aminobutyric acid (GABA) [105] | Modulate microglial activation and inflammatory responses |
| Glucocorticoids [106] | Suppresses microglia activation and inflammation via glucocorticoid receptor binding |
| Estrogen [106] | Modulates microglia activation, migration, and phagocytic activity |
| Brain-derived Neurotrophic factor (BDNF) [107] | Modulate microglial function by influencing their activation, proliferation, and release of pro-inflammatory cytokines |
| Norepinephrine [108,109] | Controls the release of inflammatory factors like interleukin 6 (IL-6), interleukin 1 β (IL-1 β), and tumor necrosis factor α (TNF- α) |
| Histamine and serotonin [111] | Increases of calcium in the microglia |




Fig. 1. Origin of microglia in mice. Microglia stem from immature erythromyeloid precursors (EMPs) that depart the yolk sac blood island around E7.5, regulated by PU.1 and RUNX. By E9.5, these EMPs reach the neuroepithelium, giving rise to embryonic microglia, which mature into the fully developed form. Essential for mature microglia's growth are IL-34 and CSF-1, vital factors that support their proliferation.

microglial homeostasis. C-myb is an important regulator of cell proliferation and survival, and its function is essential for the normal functioning and maintenance of microglia in the healthy CNS [97]. ATP release in the CNS leads to various effects, including an inflammatory response, migration, and proliferation, ultimately resulting in a microglial activation [2]. This activation is mediated through the presence of purinergic receptors on the surface of microglia, including ionotropic receptors (P2X4, P2X7) and metabotropic receptors (P2Y1, P2Y2, and P2Y12) [98,99]. Ionotropic purinergic receptors, such as P2X4 and P2X7, are involved in calcium influx and the release of pro-inflammatory molecules. Metabotropic purinergic receptors, such as P2Y1, P2Y2, and P2Y12, activate intracellular signaling cascades contributing to microglial activation and inflammation. Nerve Growth Factor (NGF) can regulate microglial activation and survival. It has been shown to modulate microglial morphology and pro-inflammatory responses [100]. Prostaglandins, including prostaglandin E2 (PGE2), can modulate microglial activation and pro-inflammatory responses. They are synthesized by microglia through cyclooxygenase 1 and 2 and can act in an autocrine or paracrine manner [101].

Notably, microglia are well known to express receptors for neurotransmitters [102–104]. Gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter

in the CNS, can also modulate microglial activation and inflammatory responses. Activation of GABA receptors on microglia has been shown to suppress their pro-inflammatory phenotype, dampening the inflammatory response [105]. Glucocorticoids and estrogen have been shown to regulate microglia function. Glucocorticoids suppress microglia activation and pro-inflammatory responses by binding to glucocorticoid receptors expressed on microglia. Estrogen modulates microglia activation, migration, and phagocytic activity [106]. Brain-Derived Neurotrophic Factor (BDNF) can modulate microglial function by influencing their activation, proliferation, and release of pro-inflammatory cytokines [107]. Norepinephrine regulates microglia and controls the release of inflammatory factors such as interleukin 6 (IL-6), interleukin 1 β (IL-1 β), and tumor necrosis factor α (TNF- α). This regulation impacts neuroinflammation, neuropathic pain, anxiety, and depression [108–110]. Histamine and Serotonin induce the increase of calcium in the microglia [111]. Microglia and neurons communicate through receptors for various neurotransmitters, enabling neurons in specific brain regions to influence microglia heterogeneity based on their combined neurotransmitter profile. The communication between microglia and neurons via neurotransmitter receptors may be crucial for brain region-specific differences, given variances in neuron-derived transmitter profiles.

Microglia in disease

Emerging research has shown that microglia represent a highly heterogeneous population composed of distinct subpopulations with diverse functions (Table 1). Dysregulation of these subpopulations has been implicated in various neurological and neurodegenerative diseases. Here are some examples of microglial subpopulations involved in specific diseases: Activation of microglia in brain diseases mostly functions through the ligation of PRRs, including the Toll-like receptor family, the scavenger receptors, CD47, CD36, and several others that cooperate to induce downstream immune signaling pathways [79–81]. Various cytokines, such as interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α), can modulate microglial activation and immune responses. They can be released by microglia themselves or by other cells in the CNS [112]. Consequently, microglia adopt disease-specific states (Table 3), which still must be defined in greater detail, as most of the existing literature is of cross-sectional nature and may not fully account for highly dynamic changes along the respective disease trajectories. Nevertheless, AD is linked to amyloid-beta plaques from increased amyloid precursor protein (APP) production or clearance issues and hyperphosphorylated tau protein buildup [113–115]. Disease-associated microglia (DAMs) and Neurodegenerative microglia (MGnD) represent a subset of microglia with heightened expression of AD-risk-associated genes (ApoE, Trem2, and Clec7a) and functional activation of the TREM2-APOE pathway [40,42]. Disease-associated microglia is associated with protective phagocytosis, and MGnD is a dysfunctional microglial phenotype [116]. While many genes differ in DAM and MGnD

between mice and humans, they share some similarities. Notably, both human microglia and activated mouse microglia show increased APOE expression, along with a reduced TREM2 expression [42,117,118]. They play a role in amyloid-beta plaque clearance and may have both protective and harmful effects on AD pathogenesis [40]. In AD, the CD33 transmembrane receptor is mainly expressed by microglia, which regulates innate immune responses [119,120]. Parkinson’s disease (PD, a movement disorder caused by the degeneration of dopaminergic neurons) is characterized by motor impairment and the presence of intraneuronal inclusions called Lewy bodies, which represent aggregates of misfolded alpha-synuclein [121]. During the course of PD, reactive microglia also become activated by alpha-synuclein and release pro-inflammatory cytokines and oxidative stress-inducing factors, contributing to PD-associated neuroinflammation and likely causing dopaminergic neuron loss [122,123]. Multiple Sclerosis (MS) is characterized by multifocal white matter lesions. Experimental Autoimmune Encephalomyelitis (EAE) serves as an animal model for studying inflammatory demyelination disease [124–126]. Both neuroinflammatory and neurodegenerative models develop double-positive TNF-alpha- and GM-CSF-producing cells, this subset abundance correlated best with the height of neuroinflammatory condition in the MS model [124]. Within EAE lesion sites, three distinct subtypes, namely daMG2, daMG3, and daMG4, have been identified. These subtypes exhibit variations in the expression of particular chemokines and cytokines, and they also exert differing effects on homeostatic markers such as P2RY12 and TMEM119 [51]. The expression of 5D4-KSPG is elevated within a specific subgroup of microglia that are positive for IBA1/CD11b in the context of amyotrophic lateral sclerosis (ALS) and in a Wallerian degeneration mouse model for spinal cord injury [57,127,128]. In stroke, pro-inflammatory microglia can become activated and exhibit a pro-inflammatory phenotype. These microglia produce inflammatory cytokines and reactive oxygen species, contributing to secondary brain damage [129]. In autism spectrum disorder (ASD), microglia show impaired synaptic pruning. These microglia fail to efficiently eliminate excessive synapses during brain development, potentially leading to disrupted or dysfunctional neural circuits and subsequently altered connectivity [130]. In brain tumors, the analysis of activated microglia using CyTOF, which is a single-cell-based immune phenotyping technique that relies on time-of-flight mass cytometry, has revealed significant differential expressions of HLA-DR, TREM2, and APOE. [131].

Table 3. Microglia in disease.

| Microglia identity | Present in |
|---|---|
| Disease-associated microglia (DAM) & Neurodegenerative microglia (MGnD) [40,42] | Alzheimer’s disease AD model |
| Reactive microglia [122] | Parkinson’s disease Alzheimer’s disease PD model |
| Double-positive TNF-alpha- and GM-CSF-producing cells [124] | Multiple sclerosis MS model |
| daMG2, daMG3, and daMG4 [51] | Expexrimental autoimmune encephalomyelitis EAE model |
| 5D4-KSPG [57] | Amyotrophic lateral sclerosis ALS model |

In summary, microglia are diverse and dynamic cells with important functions in the CNS and during CNS disorders. Understanding their origin, distribution, and subpopulations is crucial for unraveling their roles in both healthy and diseased conditions. Further research in this field will contribute to a deeper understanding of microglial biology and help to identify potential therapeutic interventions for CNS disorders.

Acknowledgments

This work was supported by funding from the Fonds National de la Recherche Luxembourg (FNR) within the PEARL program (FNR/16745220) to MTH, the EU Joint Programme—Neurodegenerative Disease Research (JPND/17063008) to MTH, the Gerhard und Ilse Schick Stiftung and the Luxembourg Centre for Systems Biomedicine (LCSB). The authors would like to thank Dr Arnaud Mary for his help to refine the manuscript.

Conflict of interest

The authors declare no conflict of interest.

Author contributions

SD authored the manuscript, and MTH edited and enhanced it, contributing to its refinement.

References

- Lehnardt S (2010) Innate immunity and neuroinflammation in the CNS: the role of microglia in toll-like receptor-mediated neuronal injury. *Glia* **58**, 253–263.
- Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML and Gan W-B (2005) ATP mediates rapid microglial response to local brain injury in vivo. *Nat Neurosci* **8**, 752–758.
- Nimmerjahn A, Kirchhoff F and Helmchen F (2005) Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. *Science* **308**, 1314–1318.
- Graeber MB (2010) Changing face of microglia. *Science* **330**, 783–788.
- Hughes V (2012) Microglia: the constant gardeners. *Nature* **485**, 570–572.
- Tremblay M-È, Lowery RL and Majewska AK (2010) Microglial interactions with synapses are modulated by visual experience. *PLoS Biol* **8**, e1000527.
- Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, Giustetto M, Ferreira TA, Guiducci E, Dumas L *et al.* (2011) Synaptic pruning by microglia is necessary for normal brain development. *Science* **333**, 1456–1458.
- Perry VH, Nicoll JAR and Holmes C (2010) Microglia in neurodegenerative disease. *Nat Rev Neurol* **6**, 193–201.
- Mittelbronn M, Dietz K, Schluesener HJ and Meyermann R (2001) Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. *Acta Neuropathol* **101**, 249–255.
- Rio-Hortega P (1939) The microglia. *Lancet* **233**, 1023–1026.
- Rezaie P and Male D (2002) Mesoglia & microglia – a historical review of the concept of mononuclear phagocytes within the central nervous system. *J Hist Neurosci* **11**, 325–374.
- Ashwell K (1990) Microglia and cell death in the developing mouse cerebellum. *Dev Brain Res* **55**, 219–230.
- Ashwell KWS and Waite PME (1991) Cell death in the developing trigeminal nuclear complex of the rat. *Dev Brain Res* **63**, 291–295.
- Sorokin SP, Hoyt RF Jr, Blunt DG and McNelly NA (1992) Macrophage development: II. Early ontogeny of macrophage populations in brain, liver, and lungs of rat embryos as revealed by a lectin marker. *Anat Rec* **232**, 527–550.
- Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng LG, Stanley ER *et al.* (2010) Fate mapping analysis reveals that adult microglia derive from primitive macrophages. *Science* **330**, 841–845.
- Hoeffel G, Wang Y, Greter M, See P, Teo P, Malleret B, Leboeuf M, Low D, Oller G, Almeida F *et al.* (2012) Adult Langerhans cells derive predominantly from embryonic fetal liver monocytes with a minor contribution of yolk sac-derived macrophages. *J Exp Med* **209**, 1167–1181.
- Schulz C, Perdiguero EG, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K, Prinz M, Wu B, Jacobsen SEW, Pollard JW *et al.* (2012) A lineage of myeloid cells independent of Myb and hematopoietic stem cells. *Science* **336**, 86–90.
- Gomez Perdiguero E, Klapproth K, Schulz C, Busch K, Azzoni E, Crozet L, Garner H, Trouillet C, de Bruijn MF, Geissmann F *et al.* (2015) Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. *Nature* **518**, 547–551.
- Hoeffel G, Chen J, Lavin Y, Low D, Almeida FF, See P, Beaudin AE, Lum J, Low I, Forsberg EC *et al.* (2015) C-Myb⁺ Erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages. *Immunity* **42**, 665–678.
- Walls JR, Coultas L, Rossant J and Henkelman RM (2008) Three-dimensional analysis of vascular development in the mouse embryo. *PLoS One* **3**, e2853.

- 21 Jones EAV (2011) The initiation of blood flow and flow induced events in early vascular development. *Semin Cell Dev Biol* **22**, 1028–1035.
- 22 Kierdorf K and Prinz M (2013) Factors regulating microglia activation. *Front Cell Neurosci* **7**, 44.
- 23 Roumier A, Pascual O, Bechade C, Wakselman S, Ponce JC, Real E, Triller A and Bessis A (2008) Prenatal activation of microglia induces delayed impairment of glutamatergic synaptic function. *PLoS One* **3**, e2595.
- 24 Arnoux I, Hoshiko M, Mandavy L, Avignone E, Yamamoto N and Audinat E (2023) Adaptive phenotype of microglial cells during the normal postnatal development of the somatosensory “Barrel” cortex. *Glia* **61**, 1582–1594.
- 25 Swinnen N, Smolders S, Avila A, Notelaers K, Paesen R, Ameloot M, Brône B, Legendre P and Rigo J-M (2013) Complex invasion pattern of the cerebral cortex by microglial cells during development of the mouse embryo. *Glia* **61**, 150–163.
- 26 Nikodemova M, Kimyon RS, De I, Small AL, Collier LS and Watters JJ (2015) Microglial numbers attain adult levels after undergoing a rapid decrease in cell number in the third postnatal week. *J Neuroimmunol* **278**, 280–288.
- 27 Hutchins KD, Dickson DW, Rashbaum WK and Lyman WD (1990) Localization of morphologically distinct microglial populations in the developing human fetal brain: implications for ontogeny. *Dev Brain Res* **55**, 95–102.
- 28 Rezaie P, Dean A, Male D and Ulfing N (2005) Microglia in the Cerebral Wall of the human telencephalon at second trimester. *Cereb Cortex* **15**, 938–949.
- 29 Monier A, Adle-Biasette H, Delezoide A-L, Evrard P, Gressens P and Verney C (2007) Entry and distribution of microglial cells in human embryonic and fetal cerebral cortex. *J Neuropathol Exp Neurol* **66**, 372–382.
- 30 Verney C, Monier A, Fallet-Bianco C and Gressens P (2010) Early microglial colonization of the human forebrain and possible involvement in periventricular white-matter injury of preterm infants. *J Anat* **217**, 436–448.
- 31 Rezaie P and Male D (1999) Colonisation of the developing human brain and spinal cord by microglia: a review. *Microsc Res Tech* **45**, 359–382.
- 32 Esiri MM, al Izzi MS and Reading MC (1991) Macrophages, microglial cells, and HLA-DR antigens in fetal and infant brain. *J Clin Pathol* **44**, 102–106.
- 33 Rezaie P (2003) Microglia in the human nervous system during development. *Neuroembryology* **2**, 18–31.
- 34 Herbomel P, Thisse B and Thisse C (1999) Ontogeny and behaviour of early macrophages in the zebrafish embryo. *Development* **126**, 3735–3745.
- 35 Herbomel P, Thisse B and Thisse C (2001) Zebrafish early macrophages colonize cephalic mesenchyme and developing brain, retina, and epidermis through a M-CSF receptor-dependent invasive process. *Dev Biol* **238**, 274–288.
- 36 Schlegelmilch K, Mohseni M, Kirak O, Pruszek J, Rodriguez JR, Zhou D, Kreger BT, Vasioukhin V, Avruch J, Brummelkamp TR *et al.* (2011) Yap1 acts downstream of α -catenin to control epidermal proliferation. *Cell* **144**, 782–795.
- 37 Lawson LJ, Perry VH, Dri P and Gordon S (1990) Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. *Neuroscience* **39**, 151–170.
- 38 Grabert K, Michael T, Karavolos MH, Clohisey S, Baillie JK, Stevens MP, Freeman TC, Summers KM and McColl BW (2016) Microglial brain region-dependent diversity and selective regional sensitivities to aging. *Nat Neurosci* **19**, 504–516.
- 39 Bennett ML, Bennett FC, Liddel SA, Ajami B, Zamanian JL, Fernhoff NB, Mulinyawe SB, Bohlen CJ, Adil A, Tucker A *et al.* (2016) New tools for studying microglia in the mouse and human CNS. *Proc Natl Acad Sci USA* **113**, E1738–E1746.
- 40 Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B *et al.* (2017) A unique microglia type associated with restricting development of Alzheimer’s disease. *Cell* **169**, 1276–1290.e17.
- 41 Galatro TF, Holtman IR, Lerario AM, Vainchtein ID, Brouwer N, Sola PR, Veras MM, Pereira TF, Leite REP, Möller T *et al.* (2017) Transcriptomic analysis of purified human cortical microglia reveals age-associated changes. *Nat Neurosci* **20**, 1162–1171.
- 42 Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O’Loughlin E, Xu Y, Fanek Z *et al.* (2017) The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. *Immunity* **47**, 566–581.e9.
- 43 Nakanishi A, Kaneko N, Takeda H, Sawasaki T, Morikawa S, Zhou W, Kurata M, Yamamoto T, Akbar SMF, Zako T *et al.* (2018) Amyloid β directly interacts with NLRP3 to initiate inflammasome activation: identification of an intrinsic NLRP3 ligand in a cell-free system. *Inflamm Regen* **38**, 27.
- 44 Masuda T, Sankowski R, Staszewski O, Böttcher C, Amann L, Sagar, Scheiwe C, Nessler S, Kunz P, van Loo G *et al.* (2019) Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. *Nature* **566**, 388–392.
- 45 Stratoulas V, Venero JL, Tremblay ME and Joseph B (2019) Microglial subtypes: diversity within the microglial community. *EMBO J* **38**, e101997.

- 46 Rio-Hortega P (1919) "Tercer elemento" de Los Centros Nerviosos. II. Intervencion de la microglia en los procesos patologicos (Cellulas en bastocito y cuerpos granulo-adiposos). *Bol Soc Esp Biol* **9**, 91–103.
- 47 Gosselin D, Link VM, Romanoski CE, Fonseca GJ, Eichenfield DZ, Spann NJ, Stender JD, Chun HB, Garner H, Geissmann F *et al.* (2014) Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. *Cell* **159**, 1327–1340.
- 48 Gosselin D, Skola D, Coufal NG, Holtman IR, Schlachetzki JCM, Sajti E, Jaeger BN, O'Connor C, Fitzpatrick C, Pasillas MP *et al.* (2017) An environment-dependent transcriptional network specifies human microglia identity. *Science* **356**, eaal3222.
- 49 Doorn KJ, Brevé JJP, Drukarch B, Boddeke HW, Huitinga I, Lucassen PJ and van Dam A-M (2015) Brain region-specific gene expression profiles in freshly isolated rat microglia. *Front Cell Neurosci* **9**, 84.
- 50 de Haas AH, Boddeke HW and Biber K (2008) Region-specific expression of immunoregulatory proteins on microglia in the healthy CNS. *Glia* **56**, 888–894.
- 51 Jordão MJC, Sankowski R, Brendecke SM, Sagar N, Locatelli G, Tai Y-H, Tay TL, Schramm E, Armbruster S, Hagemeyer N *et al.* (2019) Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammation. *Science* **363**, eaat7554.
- 52 Baalman K, Marin MA, Ho TS-Y, Godoy M, Cherian L, Robertson C and Rasband MN (2015) Axon initial segment-associated microglia. *J Neurosci* **35**, 2283–2292.
- 53 Wogram E, Wendt S, Matyash M, Pivneva T, Draguhn A and Kettenmann H (2016) Satellite microglia show spontaneous electrical activity that is uncorrelated with activity of the attached neuron. *Eur J Neurosci* **43**, 1523–1534.
- 54 Ri-o-Hortega P (1919) "Tercer elemento" de Los Centros Nerviosos II. Intervencion de la microglia en los procesos patologicos (Cellulas en bastocito y cuerpos granulo-adiposos). *Bol Soc Esp Biol* **9**, 91–103.
- 55 Bertolotto A, Agresti C, Castello A, Manzardo E and Riccio A (1998) 5D4 keratan sulfate epitope identifies a subset of ramified microglia in normal central nervous system parenchyma. *J Neuroimmunol* **85**, 69–77.
- 56 Bertolotto A, Caterson B, Canavese G, Migheli A and Schiffer D (1993) Monoclonal antibodies to keratan sulfate immunolocalize ramified microglia in paraffin and cryostat sections of rat brain. *J Histochem Cytochem* **41**, 481–487.
- 57 Hirano K, Ohgomori T, Kobayashi K, Tanaka F, Matsumoto T, Natori T, Matsuyama Y, Uchimura K, Sakamoto K, Takeuchi H *et al.* (2013) Ablation of Keratan sulfate accelerates early phase pathogenesis of ALS. *PLoS One* **8**, e66969.
- 58 Shigemoto-Mogami Y, Hoshikawa K, Goldman JE, Sekino Y and Sato K (2014) Microglia enhance neurogenesis and oligodendrogenesis in the early postnatal subventricular zone. *J Neurosci* **34**, 2231–2243.
- 59 Xavier ALR, Kress BT, Goldman SA, Lacerda de Menezes JR and Nedergaard M (2015) A distinct population of microglia supports adult neurogenesis in the subventricular zone. *J Neurosci* **35**, 11848–11861.
- 60 Xavier AL, Lima FRS, Nedergaard M and Menezes JRL (2015) Ontogeny of CX3CR1-EGFP expressing cells unveil microglia as an integral component of the postnatal subventricular zone. *Front Cell Neurosci* **9**, 37.
- 61 Chen S-K, Tvrdik P, Peden E, Cho S, Wu S, Spangrude G and Capecchi MR (2010) Hematopoietic origin of pathological grooming in Hoxb8 mutant mice. *Cell* **141**, 775–785.
- 62 Nagarajan N, Jones BW, West PJ, Marc R and Capecchi MR (2018) Corticostriatal circuit defects in Hoxb8 mutant mice. *Mol Psychiatry* **23**, 1–10.
- 63 De S, Van Deren D, Peden E, Hockin M, Boulet A, Titen S and Capecchi MR (2018) Two distinct ontogenies confer heterogeneity to mouse brain microglia. *Development* **145**, dev152306.
- 64 Wlodarczyk A, Holtman IR, Krueger M, Yogev N, Bruttger J, Khoroshii R, Benmamar-Badel A, de Boer-Bergsma JJ, Martin NA, Karram K *et al.* (2017) A novel microglial subset plays a key role in myelinogenesis in developing brain. *EMBO J* **36**, 3292–3308.
- 65 Bisht K, Sharma KP, Lecours C, Gabriela Sánchez M, El Hajj H, Miliot G, Olmos-Alonso A, Gómez-Nicola D, Luheshi G, Vallières L *et al.* (2016) Dark microglia: a new phenotype predominantly associated with pathological states. *Glia* **64**, 826–839.
- 66 Hui CW, St-Pierre A, El Hajj H, Remy Y, Hébert SS, Luheshi GN, Srivastava LK and Tremblay M-È (2018) Prenatal immune challenge in mice leads to partly sex-dependent behavioral, microglial, and molecular abnormalities associated with schizophrenia. *Front Mol Neurosci* **11**, 13.
- 67 Yeh FL, Hansen DV and Sheng M (2017) TREM2, microglia, and neurodegenerative diseases. *Trends Mol Med* **23**, 512–533.
- 68 Schmid CD, Sautkulis LN, Danielson PE, Cooper J, Hasel KW, Hilbush BS, Sutcliffe JG and Carson MJ (2002) Heterogeneous expression of the triggering receptor expressed on myeloid cells-2 on adult murine microglia. *J Neurochem* **83**, 1309–1320.
- 69 Forabosco P, Ramasamy A, Trabzuni D, Walker R, Smith C, Bras J, Levine AP, Hardy J, Pocock JM, Guerreiro R *et al.* (2013) Insights into TREM2 biology

- by network analysis of human brain gene expression data. *Neurobiol Aging* **34**, 2699–2714.
- 70 Mouton PR, Long JM, Lei D-L, Howard V, Jucker M, Calhoun ME and Ingram DK (2002) Age and gender effects on microglia and astrocyte numbers in brains of mice. *Brain Res* **956**, 30–35.
 - 71 Schwarz JM, Sholar PW and Bilbo SD (2012) Sex differences in microglial colonization of the developing rat brain. *J Neurochem* **120**, 948–963.
 - 72 Lenz KM, Nugent BM, Haliyur R and McCarthy MM (2013) Microglia are essential to masculinization of brain and behavior. *J Neurosci* **33**, 2761–2772.
 - 73 Bollinger JL, Bergeon Burns CM and Wellman CL (2016) Differential effects of stress on microglial cell activation in male and female medial prefrontal cortex. *Brain Behav Immun* **52**, 88–97.
 - 74 Guneykaya D, Ivanov A, Hernandez DP, Haage V, Wojtas B, Meyer N, Maricos M, Jordan P, Buonfiglioli A, Gielniewski B *et al.* (2018) Transcriptional and translational differences of microglia from Male and female brains. *Cell Rep* **24**, 2773–2783.e6.
 - 75 Villa A, Vegeto E, Poletti A and Maggi A (2016) Estrogens, neuroinflammation, and neurodegeneration. *Endocr Rev* **37**, 372–402.
 - 76 Thion MS, Low D, Silvín A, Chen J, Grisel P, Schulte-Schrepping J, Blecher R, Ulas T, Squarzone P, Hoeffel G *et al.* (2018) Microbiome influences prenatal and adult microglia in a sex-specific manner. *Cell* **172**, 500–516.e16.
 - 77 Wolf SA, Boddeke HWGM and Kettenmann H (2017) Microglia in physiology and disease. *Annu Rev Physiol* **79**, 619–643.
 - 78 Cuadros MA and Navascués J (1998) The origin and differentiation of microglial cells during development. *Prog Neurobiol* **56**, 173–189.
 - 79 Kawai T and Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. *Nat Immunol* **11**, 373–384.
 - 80 Kettenmann H, Hanisch U-K, Noda M and Verkhratsky A (2011) Physiology of microglia. *Physiol Rev* **91**, 461–553.
 - 81 Venegas C and Heneka MT (2017) Danger-associated molecular patterns in Alzheimer's disease. *J Leukoc Biol* **101**, 87–98.
 - 82 Barclay AN, Wright GJ, Brooke G and Brown MH (2002) CD200 and membrane protein interactions in the control of myeloid cells. *Trends Immunol* **23**, 285–290.
 - 83 Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM, Blom B, Homola ME, Streit WJ, Brown MH *et al.* (2000) Down-regulation of the macrophage lineage through interaction with OX2 (CD200). *Science* **290**, 1768–1771.
 - 84 Biber K, Neumann H, Inoue K and Boddeke HWGM (2007) Neuronal 'on' and 'off' signals control microglia. *Trends Neurosci* **30**, 596–602.
 - 85 Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A and Littman DR (2000) Analysis of Fractalkine receptor CX3CR1 function by targeted deletion and Green fluorescent protein reporter gene insertion. *Mol Cell Biol* **20**, 4106–4114.
 - 86 Kim S-Y, Lee H, Kim H-J, Bang E, Lee S-H, Lee D-W, Woo D-C, Choi C-B, Hong KS, Lee C *et al.* (2011) In vivo and ex vivo evidence for ketamine-induced hyperglutamatergic activity in the cerebral cortex of the rat: potential relevance to schizophrenia. *NMR Biomed* **24**, 1235–1242.
 - 87 Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A and Schall TJ (1997) A new class of membrane-bound chemokine with a CX3C motif. *Nature* **385**, 640–644.
 - 88 Pan Y, Lloyd C, Zhou H, Dolich S, Deeds J, Gonzalo J-A, Vath J, Gosselin M, Ma J, Dussault B *et al.* (1997) Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. *Nature* **387**, 611–617.
 - 89 Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, McNamara RK, Streit WJ, Salafranca MN, Adhikari S, Thompson DA *et al.* (1998) Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. *Proc Natl Acad Sci USA* **95**, 10896–10901.
 - 90 van Beek EM, Cochrane F, Barclay AN and van den Berg TK (2005) Signal regulatory proteins in the immune system. *J Immunol* **175**, 7781–7787.
 - 91 Ayata P, Badimon A, Strasburger HJ, Duff MK, Montgomery SE, Loh YE, Ebert A, Pimenova AA, Ramirez BR, Chan AT *et al.* (2018) Epigenetic regulation of brain region-specific microglia clearance activity. *Nat Neurosci* **21**, 1049–1060.
 - 92 Colonna M (2003) TREMs in the immune system and beyond. *Nat Rev Immunol* **3**, 445–453.
 - 93 Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH *et al.* (2015) TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. *Cell* **160**, 1061–1071.
 - 94 Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, Hernandez M and Colonna M (2006) Cutting edge: TREM-2 attenuates macrophage activation. *J Immunol* **177**, 3520–3524.
 - 95 Elmore MRP, Najafi AR, Koike MA, Dagher NN, Spangenberg EE, Rice RA, Kitazawa M, Matusow B, Nguyen H, West BL *et al.* (2014) CSF1 receptor signaling is necessary for microglia viability, which unmasks a cell that rapidly repopulates the microglia-depleted adult brain. *Neuron* **82**, 380–397.
 - 96 Dai X-M, Ryan GR, Hapel AJ, Dominguez MG, Russell RG, Kapp S, Sylvestre V and Stanley ER (2002) Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency,

- increased primitive progenitor cell frequencies, and reproductive defects. *Blood* **99**, 111–120.
- 97 Michell-Robinson MA, Touil H, Healy LM, Owen DR, Durafourt BA, Bar-Or A, Antel JP and Moore CS (2015) Roles of microglia in brain development, tissue maintenance and repair. *Brain* **138**, 1138–1159.
 - 98 Inoue K (2002) Microglial activation by purines and pyrimidines. *Glia* **40**, 156–163.
 - 99 Haynes SE, Hollopeter G, Yang G, Kurpius D, Dailey ME, Gan W-B and Julius D (2006) The P2Y₁₂ receptor regulates microglial activation by extracellular nucleotides. *Nat Neurosci* **9**, 1512–1519.
 - 100 De Simone R, Ambrosini E, Carnevale D, Ajmone-Cat MA and Minghetti L (2007) NGF promotes microglial migration through the activation of its high affinity receptor: modulation by TGF- β . *J Neuroimmunol* **190**, 53–60.
 - 101 Niraula A, Fasnacht RD, Ness KM, Frey JM, Cuschieri SA, Dorfman MD and Thaler JP (2023) Prostaglandin PGE₂ receptor EP4 regulates microglial phagocytosis and increases susceptibility to diet-induced obesity. *Diabetes* **72**, 233–244.
 - 102 McMullan SM, Phanavanh B, Guo Li G and Barger SW (2012) Metabotropic glutamate receptors inhibit microglial glutamate release. *ASN Neuro* **4**, e00094.
 - 103 Noda M, Nakanishi H, Nabekura J and Akaike N (2000) AMPA–Kainate subtypes of glutamate receptor in rat cerebral microglia. *J Neurosci* **20**, 251–258.
 - 104 Sivakumar V, Ling E-A, Lu J and Kaur C (2010) Role of glutamate and its receptors and insulin-like growth factors in hypoxia induced periventricular white matter injury. *Glia* **58**, 507–523.
 - 105 Bhandage AK and Barragan A (2021) GABAergic signaling by cells of the immune system: more the rule than the exception. *Cell Mol Life Sci* **78**, 5667–5679.
 - 106 Sierra A, Gottfried-Blackmore A, Milner TA, McEwen BS and Bulloch K (2008) Steroid hormone receptor expression and function in microglia. *Glia* **56**, 659–674.
 - 107 Parkhurst CN, Yang G, Ninan I, Savas JN, Yates JR, Lafaille JJ, Hempstead BL, Littman DR and Gan W-B (2013) Microglia promote learning-dependent synapse formation through BDNF. *Cell* **155**, 1596–1609.
 - 108 Feinstein DL, Heneka MT, Gavriluk V, Russo CD, Weinberg G and Galea E (2002) Noradrenergic regulation of inflammatory gene expression in brain. *Neurochem Int* **41**, 357–365.
 - 109 Hammerschmidt T, Kummer MP, Terwel D, Martinez A, Gorji A, Pape H-C, Rommelfanger KS, Schroeder JP, Stoll M, Schultze J *et al.* (2013) Selective loss of noradrenaline exacerbates early cognitive dysfunction and synaptic deficits in APP/PS1 mice. *Biol Psychiatry* **73**, 454–463.
 - 110 Heneka MT, Nadrigny F, Regen T, Martinez-Hernandez A, Dumitrescu-Ozimek L, Terwel D, Jandanhazi-Kurutz D, Walter J, Kirchhoff F, Hanisch UK *et al.* (2010) Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. *Proc Natl Acad Sci USA* **107**, 6058–6063.
 - 111 Pannell M, Szulzewsky F, Matyash V, Wolf SA and Kettenmann H (2014) The subpopulation of microglia sensitive to neurotransmitters/neurohormones is modulated by stimulation with LPS, interferon- γ , and IL-4. *Glia* **62**, 667–679.
 - 112 Liu X and Quan N (2018) Microglia and CNS Interleukin-1: beyond immunological concepts. *Front Neurol* **9**, 8.
 - 113 Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE and Bateman RJ (2010) Decreased clearance of CNS β -amyloid in Alzheimer's disease. *Science* **330**, 1774.
 - 114 Sarlus H and Heneka MT (2017) Microglia in Alzheimer's disease. *J Clin Invest* **127**, 3240–3249.
 - 115 Johnson GVW and Stoothoff WH (2004) Tau phosphorylation in neuronal cell function and dysfunction. *J Cell Sci* **117**, 5721–5729.
 - 116 Wei Y and Li X (2022) Different phenotypes of microglia in animal models of Alzheimer disease. *Immun Ageing* **19**, 44.
 - 117 Wang H (2021) Microglia heterogeneity in Alzheimer's disease: insights from single-cell technologies. *Frontiers in synaptic Neuroscience* **13**, 773590.
 - 118 Mathys H, Davila-Velderrain J, Peng Z, Gao F, Mohammadi S, Young JZ, Menon M, He L, Abdurrob F, Jiang X *et al.* (2019) Single-cell transcriptomic analysis of Alzheimer's disease. *Nature* **570**, 332–337.
 - 119 Gingrich MB and Traynelis SF (2000) Serine proteases and brain damage – is there a link? *Trends Neurosci* **23**, 399–407.
 - 120 Jiang T, Yu J-T, Hu N, Tan M-S, Zhu X-C and Tan L (2014) CD33 in Alzheimer's disease. *Mol Neurobiol* **49**, 529–535.
 - 121 Spillantini MG, Crowther RA, Jakes R, Hasegawa M and Goedert M (1998) α -Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. *Proc Natl Acad Sci USA* **95**, 6469–6473.
 - 122 McGeer PL, Itagaki S, Boyes BE and McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. *Neurology* **38**, 1285.
 - 123 Hirsch L, Jette N, Frolkis A, Steeves T and Pringsheim T (2016) The incidence of Parkinson's disease: a systematic review and meta-analysis. *Neuroepidemiology* **46**, 292–300.
 - 124 Milo R and Kahana E (2010) Multiple sclerosis: geoeidemiology, genetics and the environment. *Autoimmun Rev* **9**, A387–A394.
 - 125 Miron VE, Boyd A, Zhao J-W, Yuen TJ, Ruckh JM, Shadrach JL, van Wijngaarden P, Wagers AJ,

- Williams A, Franklin RJM *et al.* (2013) M2 microglia/macrophages drive oligodendrocyte differentiation during CNS remyelination. *Nat Neurosci* **16**, 1211–1218.
- 126 Ajami B, Samusik N, Wieghofer P, Ho PP, Crotti A, Bjornson Z, Prinz M, Fantl WJ, Nolan GP and Steinman L (2018) Single-cell mass cytometry reveals distinct populations of brain myeloid cells in mouse neuroinflammation and neurodegeneration models. *Nat Neurosci* **21**, 541–551.
- 127 Foyez T, Takeda-Uchimura Y, Ishigaki S, Narentuya, Zhang Z, Sobue G, Kadomatsu K and Uchimura K (2015) Microglial Keratan sulfate epitope elicits in central nervous tissues of transgenic model mice and patients with amyotrophic lateral sclerosis. *Am J Pathol* **185**, 3053–3065.
- 128 Shinjo R, Imagama S, Ito Z, Ando K, Nishida Y, Ishiguro N and Kadomatsu K (2014) Keratan sulfate expression is associated with activation of a subpopulation of microglia/macrophages in Wallerian degeneration. *Neurosci Lett* **579**, 80–85.
- 129 Wang SB, Wang YY, Zhang QE, Wu SL, Ng CH, Ungvari GS, Chen L, Wang CX, Jia FJ and Xiang YT (2018) Cognitive behavioral therapy for post-stroke depression: a meta-analysis. *J Affect Disord* **235**, 589–596.
- 130 Schaefer GB (2016) Clinical genetic aspects of autism Spectrum disorders. *Int J Mol Sci* **17**, 180.
- 131 Sankowski R, Böttcher C, Masuda T, Geirsdottir L, Sagar, Sindram E, Seredenina T, Muhs A, Scheiwe C, Shah MJ *et al.* (2019) Mapping microglia states in the human brain through the integration of high-dimensional techniques. *Nat Neurosci* **22**, 2098–2110.